Products for Research Use Only

Elubrixin

CAT: 0804-HY-18263A-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-18263A-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Elubrixin (SB-656933) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist. Elubrixin inhibits neutrophil CD11b upregulation (IC50 of 260.7 nM) and shape change (IC50 of 310.5 nM) . Elubrixin has the potential for inflammatory diseases research, such as inflammatory bowel disease and airway inflammation[1][2][3].
CAS Number
688763-64-6
Product Name Alternative
SB-656933
UNSPSC
12352005
Hazard Statement
H361-H373
Target
CXCR; Interleukin Related
Type
Reference compound
Related Pathways
GPCR/G Protein; Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/elubrixin.html
Solubility
10 mM in DMSO
Smiles
O=C(NC1=CC=C(Cl)C(S(=O)(N2CCNCC2)=O)=C1O)NC3=CC=CC(F)=C3Cl
Molecular Formula
C17H17Cl2FN4O4S
Molecular Weight
463.31
Precautions
P260-P280-P405-P501
References & Citations
[1]Mozaffari S, et al. Inflammatory bowel disease therapies discontinued between 2009 and 2014. Expert Opin Investig Drugs. 2015;24 (7) :949-56.|[2]Lazaar AL, et al. SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. Br J Clin Pharmacol. 2011 Aug;72 (2) :282-93.|[3]Nicholson GC, et al. A novel flow cytometric assay of human whole blood neutrophil and monocyte CD11b levels: upregulation by chemokines is related to receptor expression, comparison with neutrophil shape change, and effects of a chemokine receptor (CXCR2) antagonist. Pulm Pharmacol Ther. 2007;20 (1) :52-9.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
CXCR2; IL-8

Popular Products